Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) has drawn a 'Buy' rating from Rodman & Renshaw, which initiated coverage on the company with an $8.00 price target. The rating is based on the potential of Lucid-MS, the company's lead drug candidate, which is being developed as a first-in-class non-immunomodulatory small molecule to address neurodegeneration and disability progression in progressive multiple sclerosis (MS). This is an area where therapeutic options are currently limited, making Lucid-MS a potentially significant advancement for patients.
The $8.00 price target reflects the firm's valuation of Quantum BioPharma's development pipeline, with Lucid-MS at the forefront. The drug candidate has shown promise in preclinical models, demonstrating the ability to prevent and reverse myelin degradation, the underlying mechanism of MS. This mechanism of action sets it apart from existing immunomodulatory therapies, potentially offering a new approach to treating the disease.
Quantum BioPharma is dedicated to building a portfolio of innovative assets and biotech solutions for challenging neurodegenerative and metabolic disorders, as well as alcohol misuse disorders. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc., the company is focused on the research and development of Lucid-MS, a patented new chemical entity. The company has also developed UNBUZZD, an over-the-counter product, and retains a 19.48% ownership stake in Unbuzzd Wellness Inc., which commercializes the product. Additionally, Quantum is entitled to royalty payments of 7% of sales from UNBUZZD until payments reach $250 million, after which the royalty reduces to 3% in perpetuity.
The initiation of coverage by Rodman & Renshaw brings increased attention to Quantum BioPharma's efforts in addressing progressive MS, a condition that affects millions worldwide. With limited treatment options available, the potential approval and commercialization of Lucid-MS could fill a critical unmet medical need. The analyst's price target suggests confidence in the drug's prospects and the company's overall pipeline.
Investors and industry observers will be watching for further developments from Quantum BioPharma as it advances Lucid-MS through clinical trials. The company's innovative approach to MS treatment, if successful, could not only provide new hope for patients but also establish Quantum as a key player in the neurodegenerative disease space. For more information on Lucid-MS and Quantum BioPharma's initiatives, interested parties can visit the company's newsroom at https://nnw.fm/QNTM.
